Based on these results, the FDA approved this drug for a similar indication ... decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in July, the FDA ...
Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia ... in patients aged 12 and older and is the first drug in the anti-TFPI class to be approved in ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ (marstacimab-hncq) for routine ...
Pfizer has won European ... Union for people with severe hemophilia B and the first to be administered via a pre-filled pen or syringe for those with severe hemophilia A or B. The U.S. Food and Drug ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug ... regulatory wins for Pfizer. First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy ...
On Friday, the FDA approved BridgeBio Pharma, Inc.’s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) ...
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...
Based on these results, the FDA approved this drug for a similar indication last month ... The latest decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in ...